Anthem Biosciences IPO: Anthem Biosciences' IPO will open on July 14th and close on July 16th, 2025. Bidding for anchor investors will commence on July 11th.
Anthem Biosciences, a well-known company in the pharma and biotechnology sector, is set to enter the stock market. The company has shared the complete outline of its public issue, including the price band. This Initial Public Offering (IPO) of Anthem Biosciences will open on July 14, 2025, and investors can apply until July 16, 2025.
Issue Size and Price Determined
The company aims to raise ₹3395 crore through its IPO. The price band has been set at ₹540 to ₹570 per share. This issue will be entirely under the Offer for Sale (OFS) mechanism. This means the company will not receive any fresh capital from this issue; instead, the promoters and existing investors will sell their shares.
Opportunity for Anchor Investors Opens on July 11th
Anchor investors will have the opportunity to bid for the IPO on July 11th. Subsequently, general investors can apply between July 14th and 16th. In this issue, 50% of the shares are reserved for Qualified Institutional Buyers (QIBs), while 15% are reserved for Non-Institutional Investors (NIIs), and 35% are reserved for retail investors. The company has also reserved shares worth up to ₹8.25 crore for its employees.
Lot Size and Investment Amount
Each lot in the Anthem Biosciences IPO will consist of 26 shares. Therefore, retail investors applying for at least one lot will need to invest a minimum of ₹14,820. The maximum number of lots that can be applied for will be determined by SEBI's current guidelines and the investment limit for retail investors.
Allotment, Refund, and Listing Dates Also Determined
Information on the investors who will be allotted shares in the IPO will be announced on July 17, 2025. The refund process for investors who are not allotted shares will begin on July 18th. The crediting of shares to demat accounts is also expected to commence on the same day. Anthem Biosciences shares are expected to be listed on both the BSE and NSE exchanges on July 21st.
Company's Contribution to the Biotech Sector
Anthem Biosciences is a leading CRDMO (Contract Research, Development, and Manufacturing Organization). It provides research, formulation development, and manufacturing services to pharmaceutical companies. The company has gained a special recognition in the biotechnology sector due to its innovation-based operations. The company's clients are spread across India as well as in countries like the US, Europe, and Japan.
Company's Growth Journey
The Bangalore-based company was established in 2001 and has worked with several multinational pharmaceutical companies. The company specializes in services such as R&D, molecular research, protein engineering, and pharma manufacturing. It also has state-of-the-art research labs and production facilities.
IPO's Objective and OFS's Role
No new equity shares are being issued through the Anthem Biosciences IPO. This issue is entirely based on an Offer for Sale, in which existing promoters and investors will sell their holdings and exit. The entire proceeds from this will go to the respective shareholders, not to the company's account.
Increasing Activity in the Pharma Sector
This IPO by Anthem Biosciences is coming at a time when investor interest in the pharma and biotech sector is continuously increasing. In recent months, several pharma companies have raised capital through IPOs or Follow-on Public Offers (FPOs). In such an environment, Anthem Biosciences' entry into the market is considered another significant step for the industry.
Investors' Focus on Listing Gains
Since this issue is entirely an OFS, its focus is not on the company's funding but on the transfer of shares in the market. In such a scenario, investors will be eyeing the listing price and potential gains. If the grey market responds bly to this IPO, there could be significant activity in its shares on the listing day.
